Follmann, Dean http://orcid.org/0000-0003-4073-0393
O’Brien, Meagan P.
Fintzi, Jonathan
Fay, Michael P. http://orcid.org/0000-0002-8643-9625
Montefiori, David
Mateja, Allyson
Herman, Gary A.
Hooper, Andrea T.
Turner, Kenneth C.
Chan, Kuo- Chen http://orcid.org/0000-0002-3341-8783
Forleo-Neto, Eduardo http://orcid.org/0000-0003-1959-8156
Isa, Flonza
Baden, Lindsey R.
El Sahly, Hana M.
Janes, Holly
Doria-Rose, Nicole http://orcid.org/0000-0002-5731-3054
Miller, Jacqueline
Zhou, Honghong
Dang, Weiping
Benkeser, David http://orcid.org/0000-0002-1019-8343
Fong, Youyi
Gilbert, Peter B.
Marovich, Mary
Cohen, Myron S.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (75N91019D00024)
Article History
Received: 11 January 2023
Accepted: 7 June 2023
First Online: 17 June 2023
Competing interests
: D.F., J.F., M.P.F., D.M., A.M., H.M.E.S., H.J., N.D.-R., D.B., Y.F., and M.M. have no competing interests to declare. M.P.O. is an employee, has stock options, a patent pending, and license and royalties with Regeneron Pharmaceuticals, Inc. G.A.H. is an employee and shareholder of Regeneron and is listed on pending patents for the REGEN-COV antibody cocktail. A.H. owns stock in Regeneron and Pfizer. K.-C.C. and E.F.-N. are employees and shareholders of Regeneron. K.C.T. and F.I. are employees and shareholders of Regeneron and are listed on a pending patent. L.R.B. is the Deputy Editor for the New England Journal of Medicine and has grants from the Bill and Melinda Gates Foundation, Harvard Medical School, the National Institutes of Health, and the Wellcome Trust. J.M. is an employee of and has stock options and stock grants from Moderna. H.Z. is an employee of and has stock options from Moderna. W.D. is an employee of Moderna. P.G.B. will be serving as an unpaid advisor on Moderna’s Zika Vaccine Advisory Board. M.S.C. serves on the scientific advisory boards of Aerium, ModexX, and Atea and has consulting roles with Astra Zenica and GSK.
: We have complied with all relevant ethical regulations in analyzing these data. For COV-2069 the central or local institutional review board or ethics committee at each study center oversaw trial conduct and documentation. The central IRB was WCG-IRB For COVE a central institutional review board, Advarra, approved the protocol and the consent forms. Informed consent was obtained for all subjects in the COV-2069 and COVE trials. The ClinicalTrials.gov numbers were NCT04470472 and NCT04452318 for COVE and COV-2069, respectively.